NCT05116943 Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders
| NCT ID | NCT05116943 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Amyotrophic Lateral Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2013-08-19 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2013-08-19 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to collect CSF and blood samples that can be used in future research studies to identify potential biomarkers in blood and cerebrospinal fluid (CSF) collected in Amyotrophic Lateral Sclerosis (ALS) patients.
Eligibility Criteria
Inclusion Criteria - Patient with ALS, ALS-FTD or Similar Neurodegenerative Disease: * Clinical diagnosis of possible, laboratory-supported probable, probable or definite ALS according to modified eL Escorial criteria, suspected ALS according to original el Escorial criteria, or diagnosis of a similar neurodegenerative disorder. * Willing to provide consent, or assent, if physically unable to consent owing to disease-related muscle weakness. Inclusion Criteria - Spouse/Domestic Partner of Patients with ALS/ALS-FTD and Similar Neurodegenerative Disorder or Subject with Family History of ALS, ALS-FTD or Similar Neurodegenerative Disease: * No personal history of ALS, ALS-FTD or other motor neuron disease. * Subjects with family history of ALS, ALS-FTD the affected family member needs to be a first, second, or third degree blood relative. * Willing to provide consent. Exclusion Criteria - Subject with ALS/ALS-FTD or Similar Neurodegenerative Disease: * History of medical disorder that leaves in question whether neurological signs and symptoms potentially related to a neurodegenerative disease may be caused by another unrelated disorder. * Limited mental capacity rendering the subject unable to comply with lumbar puncture or standard phlebotomy procedures. * For lumbar puncture, an increased risk of bleeding complications or allergy to local anesthetic administered or skin antiseptic used for lumbar puncture. Exclusion Criteria - Spouse/Domestic Partner of Patients with ALS/ALS-FTD and Similar Neurodegenerative Disorder or Subject with Family History of ALS, ALS-FTD or Similar Neurodegenerative Disease: * Limited mental capacity rendering the subject unable to comply with lumbar puncture or standard phlebotomy procedures. * For lumbar puncture, an increased risk of bleeding complications or allergy to local anesthetic administered or skin antiseptic used for lumbar puncture.
Contact & Investigator
Bjorn Oskarsson, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT05116943 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Amyotrophic Lateral Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05116943 currently recruiting?
Yes, NCT05116943 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.
Where is the NCT05116943 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT05116943 clinical trial?
NCT05116943 is sponsored by Mayo Clinic. The principal investigator is Bjorn Oskarsson, MD at Mayo Clinic. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.